Latest Breaking News On - Sponsored leveli american depositary receipt - Page 7 : comparemela.com

Capital Markets Day 2023 - Ipsen Outlines Next Phase Of Growth & Transformation And Provides New Mid-Term Outlook

Capital Markets Day 2023 - Ipsen Outlines Next Phase Of Growth & Transformation And Provides New Mid-Term Outlook
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomFrance generalUnited statesAmy wolfChristelle huguetIoana piscociuIpsen euronextDavid loewNicolas boglerStewart campbellMari scheiffeleBartek bednarzAymeric le chatelierCapital markets dayChief executive officer

Medison Pharma; Ipsen: Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Medison Pharma; Ipsen: Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesFrance generalUnited kingdomIntrahepatic cholestasisGastroenterol hepatolGil gurfinkelIoana piscociuDara willisJennifer mooreMedison pharmaWalter perezNicolas boglerAmy wolfIpsen euronextStewart campbellInbal chen

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Pr

Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus.

United statesFrance generalUnited kingdomGastroenterol hepatolDara willisBinita kamathIpsen euronextGil gurfinkelMedison pharma inbal chenIntrahepatic cholestasisMedison pharmaWalter perezStewart campbellResource networkDivision headCorporate communications

Ipsen updates on E U Marketing Authorisation Application for odevixibat in Alagille syndrome

Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam

United statesFrance generalUnited kingdomJennifer mooreIoana piscociuChristelle huguetAmy wolfAsia pacificNicolas boglerIpsen euronextHead of corporate brand strategy communicationsCommittee for orphan medicinal productsCommittee for medicinal products humanEuropean society for pediatric gastroenterology hepatologyHead of researchDevelopment for ipsen

Ipsen Pharma: Ipsen updates on QM-1114 regulatory process

Ipsen Pharma: Ipsen updates on QM-1114 regulatory process
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomFrance generalAmy wolfNicolas boglerIpsen euronextIoana piscociuArbitral tribunal of the international chamberComplete response letterBiologics license applicationArbitral tribunalInternational chamberRare diseaseSponsored leveli american depositary receiptCorporate brand strategyFrench autorit